Physician profile
Michael J Sinclair
NPI 1043200181
$16,283.42
in general payments reported to CMS, 2019-2025
42 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,126 · 2020: $778 · 2021: $563 · 2022: $1,023 · 2023: $1,267 · 2024: $5,978 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,778 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $1,797 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,777.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $1,796.81 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $4,399.13 | 2024-2025 | Nexletol, Nexlizet |
| Pfizer INC. | $4,099.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,598.57 | 2019-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $846.68 | 2021-2025 | |
| Novo Nordisk INC | $834.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $716.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $571.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $440.68 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $341.95 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $294.70 | 2019-2025 | |
| Amarin Pharma, INC. | $194.03 | 2019-2021 | |
| Abbvie INC. | $189.81 | 2021-2024 | Qulipta, Ubrelvy |
| Allergan, INC. | $169.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.84 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $162.92 | 2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.